Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

To gain a better understanding of the role of somatic mutations in olaparib response, next-generation sequencing (NGS) of BRCA1 and BRCA2 was performed as part of a planned retrospective analysis of tumors from a randomized, double-blind, Phase II trial (Study 19; D0810C00019; NCT00753545) in 265 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Dougherty, Brian A., Lai, Zhongwu, Hodgson, Darren R., Orr, Maria C.M., Hawryluk, Matthew, Sun, James, Yelensky, Roman, Spencer, Stuart K., Robertson, Jane D., Ho, Tony W., Fielding, Anitra, Ledermann, Jonathan A., Barrett, J. Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546431/
https://www.ncbi.nlm.nih.gov/pubmed/28525389
http://dx.doi.org/10.18632/oncotarget.17613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546431/
https://www.ncbi.nlm.nih.gov/pubmed/28525389
http://dx.doi.org/10.18632/oncotarget.17613

Ejemplares similares